Lucaciu Roxana Liana, Coste Sorina Cezara, Hangan Adriana Corina, Iancu Mihaela, Orășan Olga Hilda, Cozma Angela, Gog Bogdan Sidonia, Procopciuc Lucia Maria
Department of Pharmaceutical Biochemistry and Clinical Laboratory, Faculty of Pharmacy, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
4th Department of Internal Medicine, Faculty of Medicine, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
Int J Mol Sci. 2025 Jun 14;26(12):5717. doi: 10.3390/ijms26125717.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a chronic progressive liver disease with a substantial impact on global health. Given that MASLD has a complex etiology, it is a multisystemic disease, a multidisciplinary approach is required when treating MASLD. The optimal drug for MASLD should diminish steatosis, fibrosis and inflammation in the liver. Although the pharmaceutical industry is still lagging in developing an approved pharmacologic therapy for MASLD, research has recently intensified, and many molecules that are in the final stages of clinical trials are expected to be approved in the coming few years. The current review updated information related to the MASLD pathogenesis, diagnosis and therapeutic options, how patients are clinically managed nowadays, and what to expect in the near future.
代谢功能障碍相关脂肪性肝病（MASLD）是一种慢性进行性肝病，对全球健康有重大影响。鉴于MASLD病因复杂，是一种多系统疾病，治疗MASLD时需要采取多学科方法。治疗MASLD的最佳药物应减少肝脏中的脂肪变性、纤维化和炎症。尽管制药行业在开发经批准的MASLD药物治疗方面仍滞后，但最近研究有所加强，预计未来几年许多处于临床试验最后阶段的分子将获得批准。本综述更新了与MASLD发病机制、诊断和治疗选择、目前患者的临床管理方式以及近期展望相关的信息。
